Table 5 ESMO-MCBS scores and comparison of OS before marketing authorization and after marketing authorization

Imatinib

GIST

A

9 – 22 months

41.1 months

≥3 months

Imatinib

DFSP

n.a.

3-year OS rate 66%

3-year OS rate 60 – 77%

No gain

Mitotane

Adrenocortical carcinoma

n.a.

3 – 9 months

No post-marketing studies

n.a.

Sunitinib

GIST

3

9 – 22 months

14.1 – 17.6 months

Gain of unknown magnitude

Sunitinib

RCC

4

10 – 13 months

18.2 – 27.2 months

≥3 months

Sorafenib

RCC

3

10 – 13 months

17.8 – 29.3 months

≥3 months

Sorafenib

HCC

3

< 6 months

5 – 10.2 months

≥3 months

Sorafenib

Thyroid carcinoma

2

2.5 – 3.5 years

2.4 – 4.7 years

Gain of unknown magnitude

Temsirolimus

RCC

4

6 – 12 months

11.6 – 18 months

≥3 months

Trabectedin

STS

1

6 months

11.9 – 19.3 months

≥3 months

Trabectedin

Ovarian cancer

2

>  30 months

16.3 – 22.2 months

No gain

Mifamurtide

Osteosarcoma

C

13 – 28 months

No post-marketing studies

n.a.

Everolimus

RCC

2

5-year survival rate 9.5%

14.8 – 32 months

n.a.

Cabozantinib

Medullary thyroid cancer

3

10-year survival rate < 40%

No post-marketing studies

n.a.

Olaparib

Ovarian cancer

2

5-year OS 44% for BRCA1 carriers, 52% for BRCA2 carriers

No post-marketing studies

n.a.

Ramucirumab

Gastric cancer

2

12 months

No post-marketing studies

n.a.

Dinutuximab

Neuroblastoma

A0

EFS rates are 30 - 40% for children with high-risk neuroblastoma

No post-marketing studies

n.a.

Lenvatinib

Thyroid cancer

2

2.5 – 3.5 years

No post-marketing studies

n.a.

Olaratumab

STS

4

11 – 15 months

No post-marketing studies

n.a.

Nanoliposomal irinotecan

Pancreatic cancer

2

< 12 months

No post-marketing studies

n.a.